BridgeBio Oncology Therapeutics (BBOT) Jefferies London Healthcare Conference 2025 summary

Company evolution and financial milestones

• Transitioned from an oncology affiliate within BridgeBio to an independent biotech in May 2024, raising $200 million in private capital.

• Dosed three clinical assets between June 2024 and March 2025, focusing on RAS and PI3Kα pathways.

• Raised $260 million in a PIPE in February 2025 and merged with Helix II, Cormorant SPAC, closing a de-SPAC transaction in August 2025 with over $380 million raised and only 39% redemption.

• Secured financial runway into 2028, enabling advancement of clinical programs.

Pipeline overview and clinical strategy

• Three clinical programs: BBO-8520 (KRAS-G12C on-off inhibitor), BBO-10203 (RAS PI3Kα breaker), and BBO-11818 (pan-KRAS on-off inhibitor), all in phase I.

• All programs will have clinical readouts within the next 6–18 months, with major data releases planned for 2025.

• Programs are designed to optimize target inhibition for patient benefit, focusing on prevalent oncogenes RAS and PI3Kα.

• Unique approach allows for combination therapies within the portfolio, aiming to improve efficacy and tolerability.

Scientific differentiation and innovation

• BBO-8520 inhibits both on and off-states of KRAS-G12C, potentially overcoming adaptive resistance and improving safety profile.

• BBO-10203 targets the RAS binding domain of PI3Kα, selectively inhibiting tumor signaling without affecting glucose homeostasis, reducing risk of hyperglycemia.

• BBO-11818 is a highly potent, selective pan-KRAS inhibitor, effective against G12D and G12V mutations, with strong preclinical efficacy.

• Combination of selective RAS and PI3Kα inhibitors is well tolerated in preclinical models, showing enhanced efficacy and no significant toxicity.